Anxiety-comorbidity to Schizophrenia Completed Phase 4 Trials for Pregabalin (DB00230)

IndicationStatusPhase
DBCOND0055450 (Anxiety-comorbidity to Schizophrenia)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01496690Pregablin for Anxiety-comorbidity in Patients With SchizophreniaTreatment